18281094. Method for Detecting Coronavirus Infection simplified abstract (SHIMADZU CORPORATION)
Contents
- 1 Method for Detecting Coronavirus Infection
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 Method for Detecting Coronavirus Infection - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Original Abstract Submitted
Organization Name
Inventor(s)
Kazuhito Tomizawa of Kumamoto-shi (JP)
Yu Nagayoshi of Kumamoto-shi (JP)
This abstract first appeared for US patent application 18281094 titled 'Method for Detecting Coronavirus Infection
Simplified Explanation
The present invention provides a method for determining whether a subject that is a mammal is at risk of suffering or suffering from COVID-19, by detecting the amount of at least one modified nucleoside in a sample derived from the subject.
- Method for determining COVID-19 risk in mammals
- Detecting modified nucleosides in a sample from the subject
Potential Applications
The technology could be used in healthcare settings to quickly assess whether a subject is at risk of suffering from COVID-19, allowing for early intervention and treatment.
Problems Solved
This technology helps in identifying individuals who are at risk of suffering from COVID-19, enabling healthcare providers to take necessary precautions and provide appropriate care.
Benefits
- Early detection of COVID-19 risk - Prompt intervention and treatment - Improved healthcare outcomes for individuals
Potential Commercial Applications
- Healthcare diagnostics companies - Hospitals and clinics - Research institutions
Possible Prior Art
There may be prior art related to the detection of modified nucleosides in samples for the purpose of assessing disease risk, but specific prior art related to COVID-19 risk assessment using this method is not known.
Unanswered Questions
How does this method compare to existing COVID-19 testing methods?
This method focuses on detecting modified nucleosides in samples, which may provide additional insights into COVID-19 risk compared to traditional testing methods like PCR or antigen tests.
What are the limitations of this method in terms of accuracy and reliability?
It is important to understand the sensitivity and specificity of this method in accurately determining COVID-19 risk in subjects, as well as any potential factors that could affect the reliability of the results.
Original Abstract Submitted
An object of the present invention is to provide a method for determining that a subject is at risk of suffering or is suffering from COVID-19. The present invention provides a method for determining whether a subject that is a mammal is at risk of suffering or suffering from COVID-19, the method including a step of detecting the amount of at least one modified nucleoside selected from the group consisting of 6-threonylcarbamoyl adenosine (tA) and 2-thiomethyl,6-threonylcarbamoyl adenosine (mstA) in a sample derived from the subject.
